Regular ArticleIncrease in prevalence of nosocomial non- Candida albicans candidaemia and the association of Candida krusei with fluconazole use
References (38)
- et al.
Predictors of adverse outcome in cancer patients with candidemia
Am J Med
(1998) - et al.
Candidaemia in an Australian teaching hospital: relationship to central line and TPN use
J Infect
(1998) - et al.
Nosocomial Candida. Epidemiology, transmission, and prevention
Infect Dis Clin North Am
(1997) - et al.
Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies
Blood
(1996) - et al.
Nosocomial acquisition of Candida parapsilosis: an epidemiologic study
Am J Med
(1993) - et al.
Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. National Nosocomial Infections Surveillance System
J Infect Dis
(1993) Epidemiology of nosocomial fungal infections, with emphasis on Candida species
Clin Infect Dis
(1995)- et al.
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
Clin Infect Dis
(1999) - et al.
Hospital-acquired candidemia. The attributable mortality and excess length of stay
Arch Intern Med
(1988) - et al.
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome
Rev Infect Dis
(1989)
Epidemiology of nosocomial fungal infections
Clin Microbiol Rev
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
N Engl J Med
Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study
J Infect Dis
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian FluconazoleProphylaxis Study Group
Clin Infect Dis
Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team
Bone Marrow Transplant
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial
Ann Intern Med
Risk factors for hospital-acquired candidemia. A matched case-control study
Arch Intern Med
Epi Info, Version 6: a word processing, database, and statistics program for epidemiology on micro-computers
Modern Industrial Statistics
Cited by (111)
Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents
2019, International Journal of Infectious DiseasesCitation Excerpt :Particularly, non-albicans Candida species constitute larger proportions of candidemia isolates than in the past years (Diekema et al., 2012). Some of these species are relatively less susceptible or resistant to fluconazole (Hope et al., 2002; Playford and Sorrell, 2007). In general, echinocandins are fungicidal against most Candida species and resistance is rare (Colombo et al., 2010; Sucher et al., 2009).
Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study
2018, Journal of InfectionCitation Excerpt :A concomitant emergence of non-albicans Candida spp. with decreased susceptibility or intrinsic resistance to fluconazole, in particular Candida krusei and Candida glabrata, has been described. This shift has been reported in breakthrough candidemia (BTC) occurring on fluconazole.8–17 A microbiological study in Candida isolates from BTC described a correlation between dose of fluconazole and minimal inhibitory concentration (MIC), without reporting related clinical data.18
Treatment of infection in burn patients
2018, Total Burn Care: Fifth EditionTreatment of Infection in Burn Patients
2017, Total Burn Care, Fifth EditionEvaluation of anticandidal and antioxidant activities of phenolic compounds from Pyrostegia venusta (Ker Gawl.) Miers
2014, Chemico-Biological InteractionsCandida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: A 6-year prospective candidaemia survey from the fungal infection network of Switzerland
2014, Clinical Microbiology and Infection
- f1
Author for correspondence: Dr W. Hope, Department of Microbiology, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba Q 4102, Australia. Fax : +61732405786; E-mail:[email protected]